Skip to main content
Canna~Fangled Abstracts

Lack of association of DRD3 and CNR1 polymorphisms with premenstrual dysphoric disorders.

By April 13, 2015No Comments
2015 Apr;13(4):221-6.

Abstract

BACKGROUND:

PM 1aPremenstrual dysphoric disorder (PMDD) is a mood disorder characterized with physical and affective symptoms during the luteal phase of susceptible women.

OBJECTIVE:

The aim of this study was to investigate the association of Dopamine D3 receptor (DRD3) polymorphism, and Cannabinoid receptor Type 1 (CNR1) polymorphism with PMDD.

MATERIALS AND METHODS:

Fifty one participants with documented PMDD according to the DSM IV criteria and 51 healthy controls were included in this cross sectional study. Symptom severity was measured with daily self-rating, monthly premenstrual assessment forms and psychiatric interviews. The genotyping of DRD3 receptor and Cannabinoid type 1 receptors were performed using Taqmanfluorogenic assay method.

RESULTS:

Distribution of DRD3 and CNR1 polymorphism was not different between patients and controls.

CONCLUSION:

These findings do not support a major role of DRD3, and CNR1 polymorphisms in contributing to susceptibility to premenstrual dysphoric disorder.

KEYWORDS:

Cannabinoid receptor; Dopamine D3 receptor; Genetic polymorphism; Premenstrual syndrome

PMID:

 

26131011

 

[PubMed]
twin memes II